Drugs / Cafusertib
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02314884 | Nov 2014 → Dec 2015 | neoplasm | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02140606 | May 2014 → Dec 2015 | acute myeloid leukemia | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cafusertib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02314884 ↗ |
| Known as | Cafusertib Hydrochloride | “Drug: Cafusertib Hydrochloride (d1 and 15) Cafusertib (d1 and 15 - one hour iv.v)” NCT02140606 ↗ |
| Action | Inhibit | “Serine/threonine-protein kinase PLK1 inhibitor” CHEMBL3545354 ↗ |
| Route | Intravenous | “one hour iv.v” NCT02140606 ↗ |
| Target | PLK1 | “Serine/threonine-protein kinase PLK1 inhibitor” CHEMBL3545354 ↗ |